Back to search

Peptide record

TPDB41211

HHH Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41211
HHH
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLLHLLHLLLHAAGW-NH2
Physicochemical Analysis
C81H126N22O16
RNDCEQIKMFPSTYV
L
1664.03
8.09
3
0
10
+0
-3.21
1.260
195.33
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
330.52
0
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
3
H
0
I
7
L
0
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 3 I: 0 L: 7 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
15
C81H126N22O16
1664.03
8.09
+0
-3.21
1.260
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 21.10 ± 6.93 µM
Anticancer
21.10

Target

Breast Cancer
HMLER
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 9.50 ± 0.99 µM
Anticancer
9.50

Target

Breast Cancer
HMLER-shEcad
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 185 ± 7 µM
Anticancer
185

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022